URGN UroGen Pharma Ltd.

36.14
-0.1  -0%
Previous Close 36.24
Open 36.15
Price To Book 8.33
Market Cap 755,246,962
Shares 20,897,813
Volume 31,351
Short Ratio
Av. Daily Volume 186,006

NewsSee all news

  1. UroGen To Host Investor Day on September 24, 2019 Spotlighting Clinical Development Updates and UGN-101 Launch Readiness

    Company to Also Participate in September Investor Conferences UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced

  2. UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced the grants of inducement restricted stock units ("RSUs") to 15

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be completed 2H 2019.
RTGel in combination with BOTOX
Overactive Bladder (OAB)
Phase 2a planned for 1H 2019.
Vesimune
Carcinoma In-Situ (CIS)
Phase 2b initial data due September 24, 2019.
VesiGel UGN-102
Low grade non-muscle invasive bladder cancer (LG-NMIBC)
Phase 3 full data due 3Q 2019. Rolling NDA 4Q 2019.
MitoGel - UGN-101
Urothelial Carcinoma

Latest News

  1. UroGen To Host Investor Day on September 24, 2019 Spotlighting Clinical Development Updates and UGN-101 Launch Readiness

    Company to Also Participate in September Investor Conferences UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced

  2. UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced the grants of inducement restricted stock units ("RSUs") to 15